Attached files
| file | filename |
|---|---|
| S-1/A - FORM S-1/A - Dicerna Pharmaceuticals Inc | d622509ds1a.htm |
| EX-10.8 - EX-10.8 - Dicerna Pharmaceuticals Inc | d622509dex108.htm |
| EX-3.3 - EX-3.3 - Dicerna Pharmaceuticals Inc | d622509dex33.htm |
| EX-10.10 - EX-10.10 - Dicerna Pharmaceuticals Inc | d622509dex1010.htm |
| EX-10.17 - EX-10.17 - Dicerna Pharmaceuticals Inc | d622509dex1017.htm |
| EX-10.9 - EX-10.9 - Dicerna Pharmaceuticals Inc | d622509dex109.htm |
| EX-10.19 - EX-10.19 - Dicerna Pharmaceuticals Inc | d622509dex1019.htm |
| EX-3.4 - EX-3.4 - Dicerna Pharmaceuticals Inc | d622509dex34.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Amendment No. 1 to Registration Statement No. 333-193150 of our report dated November 8, 2013, relating to the financial statements of Dicerna Pharmaceuticals, Inc. appearing in the Prospectus, which is a part of such Registration Statement, and to the reference to us under the heading “Experts” in such Prospectus.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
January 17, 2014